Evidence map›Paper›PMID 41417202›Full record

ReviewAnnals of nuclear medicine2026

Clinical utility and future directions of FDG-PET in rectal cancer management.

Shiyuan Gu, Leyi Yao, Jiayu Duan, Qiaoli Wang, Shang Wang, Xin Wang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shiyuan GuDivision of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Leyi YaoDivision of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Jiayu DuanDivision of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Qiaoli WangDivision of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Shang WangDivision of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
Xin WangDivision of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China. wangxin@wchscu.edu.cn.ORCID http://orcid.org/0000-0003-3599-6904

Funding

1·3·5 project for disciplines of excellence No. ZYAI24045National Natural Science Foundation of China No. 82073338Sichuan Province Science and Technology Support Program No 2022YFS0217Sichuan Province Science and Technology Support Program No. 2023YFS0319Sichuan Province Science and Technology Support Program No.2024YFFK0338
6 · The paper itself

Abstract

Fluorodeoxyglucose positron emission tomography (FDG-PET), as a representative biological imaging modality, has demonstrated unique clinical value in the comprehensive management of rectal cancer. This review summarizes the advances in the application of FDG-PET across multiple stages of rectal cancer care, with a focus on its role in assessing stages, guiding radiotherapy plans and predicting prognosis. Although challenges such as coarse granularity of parameters and false positives due to inflammation remain, emerging strategies including dual-time point imaging, multi-modality fusion evaluation, integration with molecular biomarkers, texture analysis, voxel-based modeling, and artificial intelligence have shown promise in overcoming these limitations, and are expected to drive FDG-PET from an auxiliary evaluation tool to a core platform for precision treatment of rectal cancer.

Indexed as

Fluorodeoxyglucose F18Positron-Emission TomographyRectal NeoplasmsHumansFluorodeoxyglucose F18FDG-PETRadiotherapy planningRectal cancerResponse assessmentStaging

Identifiers

PMID41417202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.